RS55405B1 - Varijantni, rekombinantni proteini beta-glukocerebrozidaze sa povećanom stabilnošću i povećanom zadržanom katalitičkom aktivnošću - Google Patents

Varijantni, rekombinantni proteini beta-glukocerebrozidaze sa povećanom stabilnošću i povećanom zadržanom katalitičkom aktivnošću

Info

Publication number
RS55405B1
RS55405B1 RS20161010A RSP20161010A RS55405B1 RS 55405 B1 RS55405 B1 RS 55405B1 RS 20161010 A RS20161010 A RS 20161010A RS P20161010 A RSP20161010 A RS P20161010A RS 55405 B1 RS55405 B1 RS 55405B1
Authority
RS
Serbia
Prior art keywords
glucocerebrosidase
wild
glccerase
variant
recombinant
Prior art date
Application number
RS20161010A
Other languages
English (en)
Serbian (sr)
Inventor
Hung Do
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of RS55405B1 publication Critical patent/RS55405B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RS20161010A 2010-11-08 2011-11-08 Varijantni, rekombinantni proteini beta-glukocerebrozidaze sa povećanom stabilnošću i povećanom zadržanom katalitičkom aktivnošću RS55405B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41133110P 2010-11-08 2010-11-08
US41218010P 2010-11-10 2010-11-10
EP11839428.7A EP2638152B1 (en) 2010-11-08 2011-11-08 Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
PCT/US2011/059731 WO2012064709A2 (en) 2010-11-08 2011-11-08 Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity

Publications (1)

Publication Number Publication Date
RS55405B1 true RS55405B1 (sr) 2017-04-28

Family

ID=46051505

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20161010A RS55405B1 (sr) 2010-11-08 2011-11-08 Varijantni, rekombinantni proteini beta-glukocerebrozidaze sa povećanom stabilnošću i povećanom zadržanom katalitičkom aktivnošću

Country Status (19)

Country Link
US (4) US8962564B2 (https=)
EP (2) EP3144386B1 (https=)
JP (2) JP6073796B2 (https=)
KR (1) KR101901467B1 (https=)
CN (2) CN105296447A (https=)
BR (1) BR112013011152A2 (https=)
CA (1) CA2817011C (https=)
CY (1) CY1118843T1 (https=)
DK (1) DK2638152T3 (https=)
ES (2) ES2743825T3 (https=)
HR (1) HRP20161560T1 (https=)
HU (1) HUE030932T2 (https=)
LT (1) LT2638152T (https=)
PL (1) PL2638152T3 (https=)
PT (1) PT2638152T (https=)
RS (1) RS55405B1 (https=)
SI (1) SI2638152T1 (https=)
SM (1) SMT201600431B (https=)
WO (1) WO2012064709A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220125892A1 (en) * 2019-02-01 2022-04-28 OXYRANE UK Ltd. Glucocerebrosidase polypeptides
KR20210148101A (ko) 2019-02-04 2021-12-07 프리라인 테라퓨틱스 리미티드 폴리뉴클레오티드
EP4028048A1 (en) * 2019-09-09 2022-07-20 F. Hoffmann-La Roche AG Glucocerebrosidase mutants
CN115348884B (zh) * 2020-03-29 2024-07-30 耶达研究及发展有限公司 用于治疗戈谢病的β-葡糖脑苷脂酶变体
KR20230042513A (ko) * 2020-07-29 2023-03-28 프리라인 테라퓨틱스 리미티드 폴리펩티드
WO2023145812A1 (ja) * 2022-01-31 2023-08-03 株式会社日本触媒 グルコセレブロシダーゼ活性を有する糖鎖付加タンパク質
JPWO2023145814A1 (https=) * 2022-01-31 2023-08-03
WO2023145813A1 (ja) * 2022-01-31 2023-08-03 株式会社日本触媒 グルコセレブロシダーゼ活性を有するタンパク質およびその製造方法
EP4508206A1 (en) 2022-04-12 2025-02-19 F. Hoffmann-La Roche AG Fusion proteins targeted to the central nervous system
CN118715316B (zh) * 2022-10-08 2025-09-19 凌意(杭州)生物科技有限公司 用于治疗GCase缺乏相关疾病的多核苷酸
TW202532096A (zh) * 2023-12-08 2025-08-16 美商戴納立製藥公司 經修飾之葡萄糖腦苷脂酶多肽及其使用方法
WO2026006173A1 (en) * 2024-06-24 2026-01-02 Denali Therapeutics Inc. Fusion proteins comprising modified glucocerebrosidase polypeptides and methods thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03503721A (ja) * 1988-12-23 1991-08-22 ジェンザイム コーポレイション 酵素的に活性な組換えグルコセレブロシダーゼ
DE68926569T2 (de) 1988-12-23 1996-09-26 Genzyme Corp Cho-zellen befähigt enzymatisch aktive rekombinante-glukocerebrosidase zu produzieren
EP0979311A1 (en) 1997-04-30 2000-02-16 Of The University Of Minnesota Regents $i(IN VIVO) USE OF RECOMBINAGENIC OLIGONUCLEOBASES TO CORRECT GENETIC LESIONS IN HEPATOCYTES
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
IL135578A0 (en) 1997-10-29 2001-05-20 Genzyme Corp Compositions and methods for treating lysosomal storage disease
WO2000012740A2 (en) 1998-08-28 2000-03-09 Duke University ADENOVIRUSES DELETED IN THE IVa2, 100K AND/OR PRETERMINAL PROTEIN SEQUENCES
US20020127219A1 (en) 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
AU2352201A (en) 1999-12-30 2001-07-16 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
WO2001077307A2 (en) 2000-04-06 2001-10-18 Exegenics, Inc. Expression system for efficiently producing clinically effective lysosomal enzymes (glucocerebrosidase)
CA2412882A1 (en) * 2000-06-30 2002-01-10 Maxygen Aps Peptide extended glycosylated polypeptides
US7855063B2 (en) * 2003-04-16 2010-12-21 Yeda Research And Development Co. Ltd. Partially deglycosylated glucocerebrosidase polypeptide and crystals thereof
WO2005089047A2 (en) 2004-03-18 2005-09-29 Glycofi, Inc. Glycosylated glucocerebrosidase expression in fungal hosts
MX2009011473A (es) * 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
CA2688850C (en) * 2007-05-22 2015-08-11 Amicus Therapeutics, Inc. New method for preparing isofagomine and its derivatives
JP5513398B2 (ja) 2007-11-02 2014-06-04 ザ スクリプス リサーチ インスティチュート 非天然アミノ酸を含有する蛋白質を使用する指向的進化
WO2009059056A2 (en) 2007-11-02 2009-05-07 The Scripps Research Institute A genetically encoded boronate amino acid

Also Published As

Publication number Publication date
ES2604490T3 (es) 2017-03-07
BR112013011152A2 (pt) 2016-11-29
US9566316B2 (en) 2017-02-14
DK2638152T3 (en) 2016-12-12
ES2743825T3 (es) 2020-02-20
EP2638152A2 (en) 2013-09-18
JP6073796B2 (ja) 2017-02-01
CN103314105A (zh) 2013-09-18
US20150216950A1 (en) 2015-08-06
US20160184408A1 (en) 2016-06-30
CA2817011A1 (en) 2012-05-18
CY1118843T1 (el) 2018-01-10
US20130344054A1 (en) 2013-12-26
JP2017099390A (ja) 2017-06-08
SMT201600431B (it) 2017-01-10
CA2817011C (en) 2019-04-02
KR101901467B1 (ko) 2018-11-02
CN105296447A (zh) 2016-02-03
PT2638152T (pt) 2016-10-25
SI2638152T1 (sl) 2016-12-30
JP2014500722A (ja) 2014-01-16
US9821038B2 (en) 2017-11-21
EP3144386A1 (en) 2017-03-22
HRP20161560T1 (hr) 2016-12-30
EP3144386B1 (en) 2019-05-29
HUE030932T2 (en) 2017-06-28
US20170157220A1 (en) 2017-06-08
LT2638152T (lt) 2016-12-12
US9254313B2 (en) 2016-02-09
JP6457559B2 (ja) 2019-01-23
PL2638152T3 (pl) 2017-02-28
CN103314105B (zh) 2015-11-25
EP2638152B1 (en) 2016-08-31
WO2012064709A2 (en) 2012-05-18
US8962564B2 (en) 2015-02-24
WO2012064709A3 (en) 2012-08-02
EP2638152A4 (en) 2014-04-09
KR20140009238A (ko) 2014-01-22

Similar Documents

Publication Publication Date Title
RS55405B1 (sr) Varijantni, rekombinantni proteini beta-glukocerebrozidaze sa povećanom stabilnošću i povećanom zadržanom katalitičkom aktivnošću
JP6587666B2 (ja) リソソーム貯蔵疾患の処置のための方法および組成物
JP7042263B2 (ja) ファブリー病の治療のための方法および組成物
EP3845651B1 (en) Novel nuclease domain and uses thereof
RS55669B1 (sr) Proizvodnja aktivne visoko fosforilisane ljudske n-acetilglaktozamin-6-sulfataze i njene primene
KR20180127319A (ko) 신경 질환의 치료를 위한 방법 및 조성물
HK1189624B (en) Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
RU2845088C2 (ru) Расщепленный с n-конца и/или c-конца растворимый полипептид ph20 и его применение
HK1235826A1 (en) Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
HK1238680A1 (en) Methods and compositions for the treatment of monogenic diseases
HK40002981B (en) Methods and compositions for the treatment of lysosomal storage diseases
HK40002981A (en) Methods and compositions for the treatment of lysosomal storage diseases
HK1238680B (en) Methods and compositions for the treatment of monogenic diseases
HK1209788B (en) Methods and compositions for the treatment of lysosomal storage diseases